fbpx

News

Lundbeckfonden Ventures News

BONESUPPORTs annual report for 2018 is now available as a pdf on the group’s web page, www.bonesupport.com. A PDF-version is also attached to this press release. About BONESUPPORT™ BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs....
Lund, Sweden, 16.00 CET, April 16, 2019 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids, today announced that the quarterly report for the first quarter of 2019 will be published on May 2 at 08.00 CET instead of as previously communicated on 8 May. This is due to the fact...
Presentation of data from multiple preclinical studies from APX001 antifungal program SAN DIEGO – April 12, 2019 – Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections, announced today that three posters from the APX001 development program will be presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), being held...
Lund, Sweden, 08.00 CET, 10 April 2019 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids, today announced the publication of new radiographic and histological data, which for the first time provides clinical evidence of CERAMENT® remodeling into bone in humans. “This publication describes for the first time in detail radiographic...
CAMBRIDGE, Mass.–(BUSINESS WIRE)– Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that it closed a $40 million Series D financing. New investor Medicxi led the round, with current investors also participating. The Company plans to use the proceeds from the Series D financing to support the late...
Lund, Sverige, 18:00 CET, 29 March 2019 – During the month of March, the number of shares and votes in BONESUPPORT HOLDING AB (publ) has increased due to directed issue and repurchase of 505,000 series C shares, which were resolved upon by the board of directors on 1 March 2019 pursuant to the authorizations granted...
CAMBRIDGE, Mass., March 29, 2019 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for SPR994, Spero’s lead...
March 13, 2019 – OXFORD, UK – PsiOxus Therapeutics, Ltd. (PsiOxus), the gene therapy for cancer company, today announced that it has started dosing NG-350A, an antibody based cancer gene therapy, to cancer patients. The Phase 1 FORTITUDE study is being conducted at multiple cancer centers in the United States and will assess the safety,...
New collaboration to evaluate the potential of bacterial antigens that mimic tumor antigens and neoantigens (“onco-mimics”) to drive immune responses Paris, France and Cambridge, MA, USA – March 20, 2019 ENTEROME SA, a clinical-stage biopharmaceutical company developing innovative therapies based on the identification and therapeutic application of bioactive molecules expressed, secreted and regulated by the...
1 2 3 56

Lundbeckfonden Ventures

News

BONESUPPORT HOLDING AB (publ) publishes Annual Report 2018
17. April 2019
BONESUPPORT will publish quarterly report earlier than previously communicated
16. April 2019
BONESUPPORTs annual report for 2018 is now available as a pdf on the group’s web page, www.bonesupport.com. A PDF-version is also attached to this press release. About BONESUPPORT™ BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver and a Premarket approval filing with the FDA (USA) for its gentamicin eluting product is planned in 2020. The company is based in Lund, Sweden, and the net sales amounted to SEK 97 million in 2018. Please visit www.bonesupport.com for more information. BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB. For more information contact: BONESUPPORT AB Emil Billbäck, CEO +46 (0) 46 286 53 70 Håkan Johansson, CFO +46(0) 46 286 53 70 ir@bonesupport.com Cord Communications Charlotte Stjerngren +46 (0)708 76 87 87 charlotte.stjerngren@cordcom.se www.cordcom.se
15. April 2019